UroGen Pharma
URGN
Market cap $521M

12.38 USD

-0.14

1.12%

Updated Oct 22, 10:49 AM EDT

1 day

-1.12%

5 days

-0.48%

1 month

-4.55%

3 months

-23.58%

6 months

-13.85%

Year to date

-18.61%

1 year

10.34%

5 years

-43.16%

About: UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Employees: 203

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 10 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

175% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 20

55% more capital invested

Capital invested by funds: $413M [Q1] → $641M (+$228M) [Q2]

50% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]

15% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 20

12.19% more ownership

Funds ownership: 80.75% [Q1] → 92.94% (+12.19%) [Q2]

3% more funds holding

Funds holding: 112 [Q1] → 115 (+3) [Q2]

25% less call options, than puts

Call options by funds: $3.18M | Put options by funds: $4.24M

See Fund Rankings

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$25

102%

upside

Avg. target

$46

271%

upside

High target

$64

417%

upside

10 analyst ratings

10 positive

100%

0 neutral

0%

0 negative

0%

EF Hutton Jason Kolbert 39% 1-year accuracy 22 / 56 met price target	102%upside $25	Buy Maintained	21 Oct 2024
EF Hutton Jason Kolbert 39% 1-year accuracy 22 / 56 met price target	102%upside $25	Buy Maintained	16 Oct 2024
Oppenheimer Leland Gershell 60% 1-year accuracy 34 / 57 met price target	223%upside $40	Outperform Reiterated	16 Oct 2024
HC Wainwright & Co. Raghuram Selvaraju 56% 1-year accuracy 133 / 239 met price target	417%upside $64	Buy Maintained	16 Oct 2024
HC Wainwright & Co. Raghuram Selvaraju 56% 1-year accuracy 133 / 239 met price target	385%upside $60	Buy Reiterated	15 Oct 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about URGN published over the past 30 days

UroGen Announces FDA Acceptance of its New Drug Application for UGN-102

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for investigational drug UGN-102 (mitomycin) for intravesical solution. UGN-102 could become the first FDA-approved medicine for the treatment of low-grade intermediate-risk non-muscle invasive bladder.

UroGen Announces FDA Acceptance of its New Drug Application for UGN-102

UroGen Appoints Chris Degnan as Chief Financial Officer

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that Chris Degnan has been appointed Chief Financial Officer. Mr. Degnan succeeds Don Kim, who is leaving UroGen to pursue other opportunities. "Under Don's financial stewardship, we have strengthened our financial position and achieved significant milestones, which include multiple ca.

UroGen Appoints Chris Degnan as Chief Financial Officer

First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the first patient was dosed in the Phase 3 clinical trial of investigational drug UGN-103 (mitomycin) for intravesical solution in development for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). UGN-103 is a next-generation novel mito.

First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Announces Patent Allowance.

UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 19 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of Jelmyto® (mitomycin) for pyelocalyceal solution, UroGen's first approved product, and the c.

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma's JELMYTO And UGN-102: A Strong Buy In The Urological Cancer Sector

UroGen Pharma stock is a strong buy due to its innovative RTGel technology and promising pipeline, including JELMYTO and UGN-102, targeting urological cancers. URGN's JELMYTO shows impressive clinical results with a 58% complete response rate for low-grade upper tract urothelial cancer, demonstrating long-lasting effects. URGN's diverse pipeline, including UGN-301 for high-grade NMIBC, positions the company for significant market expansion in urological cancer treatments.

UroGen Pharma's JELMYTO And UGN-102: A Strong Buy In The Urological Cancer Sector

UroGen Pharma to Present at Upcoming Investor Conferences

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in fireside chats at the following investor conferences in September: H.C. Wainwright 26th Annual Global Investment Conference – September 9-11th, 2024 Fireside Chat: September 9th, 2024 at 9:00am ET Location: New York, NY Webcast Registration Link: Here 2024 C.

UroGen Pharma to Present at Upcoming Investor Conferences

UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a leading biotech company specializing in novel therapies for urothelial and specialty cancers, today announced the successful completion of its New Drug Application (NDA) submission for investigational drug UGN-102, (mitomycin) for intravesical solution, a significant step forward in potentially addressing the urgent need for innovative treatments for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC.

UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Pharma Ltd. (URGN) Q2 2024 Earnings Call Transcript

UroGen Pharma Ltd. (NASDAQ:URGN ) Q2 2024 Earnings Call August 13, 2024 10:00 AM ET Company Participants Vincent Perrone - Head, Investor Relations Liz Barrett - President and Chief Executive Officer Mark Schoenberg - Chief Medical Officer David Lin - Chief Commercial Officer Dong Kim - Chief Financial Officer Conference Call Participants Tara Bancroft - TD Cowen Raghuram Selvaraju - H.C.

UroGen Pharma Ltd. (URGN) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Urogen Pharma (URGN) Reports Q2 Loss, Misses Revenue Estimates

Urogen Pharma (URGN) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $1.03 per share a year ago.

Urogen Pharma (URGN) Reports Q2 Loss, Misses Revenue Estimates

See News Rankings

Charts implemented using Lightweight Charts™